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Abstract
Background: Pruritus (itch) is a symptom commonly experienced by patients with cholestatic liver diseases such as
primary biliary cholangitis (PBC, previously referred to as primary biliary cirrhosis). Bile acids (BAs) have been proposed
as potential pruritogens in PBC. The ileal bile acid transporter (IBAT) protein expressed in the distal ileum plays a key
role in the enterohepatic circulation of BAs. Pharmacological inhibition of IBAT with GSK2330672 may reduce BA levels
in the systemic circulation and improve pruritus.
Methods: This clinical study (BAT117213 study) is sponsored by GlaxoSmithKline (GSK) with associated exploratory studies
supported by the National Institute for Health Research (NIHR). It is a phase 2a, multi-centre, randomised, double bind,
placebo controlled, cross-over trial for PBC patients with pruritus. The primary objective is to investigate the safety and
tolerability of repeat doses of GSK2330672, and explore whether GSK2330672 administration for 14 days improves pruritus
compared with placebo. The key outcomes include improvement in pruritus scores evaluated on a numerical rating scale
and other PBC symptoms in an electronic diary completed twice daily by the patients. The secondary outcomes include
the evaluation of the effect of GSK2330672 on total serum bile acid (BA) concentrations, serum markers of BA synthesis
and steady-state pharmacokinetics of ursodeoxycholic acid (UDCA).
Discussion: BAT117213 study is the first randomised controlled crossover trial of ileal bile acid transporter inhibitor, a
novel class of drug to treat pruritus in PBC. The main strengths of the trial are utility of a novel, study specific, electronic
symptom diary as patient reported outcome to measure the treatment response objectively and the crossover design
that allows estimating the treatment effect in a smaller number of patients. The outcome of this trial will inform
the trial design of future development phase of the IBAT inhibitor drug. The trial will also provide opportunity to
conduct metabonomic and gut microbiome studies as explorative and mechanistic research in patients with
cholestatic pruritus.
Trial registration: EudraCT number: 2012-005531-84, ClinicalTrials.gov Identifier: NCT01899703, registered on 3rd
July 2013
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Background
Primary biliary cholangitis (cirrhosis) (PBC) is an auto-
immune chronic cholestatic liver disease with a preva-
lence of 30/100,000, typically affecting middle aged
women (female: male ratio 10:1) [1]. In untreated cases
immunologically mediated chronic cholestasis ultimately
results in liver cirrhosis with associated complications
such as portal hypertension, varices, ascites, hepatocellu-
lar carcinoma and death. The precise aetiology of PBC is
unclear, although genetic and environmental factors are
thought to play a key role.
Pruritus (itch) is one of the characteristic symptoms of
PBC and can affect patients at any stage of the disease [2].
Recently, we studied the scale of the pruritus symptom
within the United Kingdom (UK)-PBC cohort, a national
cohort of over 3000 PBC patients recruited from every
hospital in the UK. In this cohort 60–70 % of PBC patients
reported experience of pruritus at some point in the
course of the disease, 30 % had persistent pruritus and 15
% suffered with severe pruritus since the diagnosis of PBC
[3]. A similar scale of symptom burden has also been re-
ported in PBC cohorts from USA and Italy [4]. Pruritus
has a negative impact on perceived quality of life in PBC
patients and has been associated with sleep deprivation,
worsened day time fatigue and when severe, may lead to
depression and suicidal tendencies [5].
Ursodeoxycholic acid (UDCA), the current standard of
care for PBC patients and the only licenced therapy for
PBC has no role in treating pruritus [2]. Current treat-
ment of pruritus in PBC involves step-wise use of specific
anti-pruritic agents in line with current international
guidelines [2, 6]. These drugs include cholestyramine, ri-
fampicin, naltrexone and sertraline. Of these, cholestyr-
amine is the only licensed drug for treatment of
cholestatic pruritus and use of other drugs is “off-label”.
The limitations of these drugs are that their efficacy is not
universal, treatment is often associated with side effects
and there is a need for regular monitoring for liver tox-
icity. Patients with medically refractory pruritus may ei-
ther need to undergo phototherapy, invasive interventions
such as nasobiliary drainage or extracorporeal albumin
dialysis for temporary relief of pruritus, or may be consid-
ered for liver transplantation (LT) which is typically cura-
tive. Therefore, development of better drug therapies with
fewer side effects is an unmet clinical need for PBC
patients [7].
Ileal bile acid transporter (IBAT)
Primary BAs are synthesized in the liver from an enzym-
atic catabolism of cholesterol, a process regulated by en-
zyme cytochrome P450 (CYP) 7A1. Unconjugated BAs
are conjugated in hepatocytes with glycine and taurine,
secreted into the bile and stored in the gallbladder.
Upon ingestion of a meal, conjugated BAs (“bile salts”)
are released into the intestinal lumen where they facili-
tate absorption of fat and fat soluble vitamins. After
their normal physiological function is completed in the
intestine, BAs reach the ileum where they are reab-
sorbed. The ileal bile acid transporter [(IBAT), also
called apical sodium dependent bile acid transporter
(ASBT)], is a protein predominantly located in the ter-
minal ileum and serves as the main transporter mediat-
ing the ileal uptake of conjugated BAs and their return
to the liver via the portal circulation (enterohepatic
circulation) [8].
Bile salts (and their protonated form, BAs) have been
suggested to play role in the pathogenesis of pruritus in
cholestatic conditions. In cholestasis, the ileal uptake of
BAs has been shown to be upregulated [9]. Also, the evi-
dence that pruritus dramatically improves in patients
undergoing nasobiliary drainage [10] and is effectively
cured by LT [11] suggests a direct or indirect role for
BAs in mediating cholestatic pruritus. Therefore a
pharmaceutical agent that can reduce their levels in the
enterohepatic and systemic circulations may be pre-
dicted to improve pruritus. In two animal studies treat-
ment with IBAT inhibitors SC-435 and A4250 produced
BA malabsorption and attenuated BA-mediated chole-
static liver injury by reducing biliary BA output [12, 13].
In humans, use of IBAT inhibitor A4250 has been
shown to decrease the serum BAs and increase faecal
BAs by highly efficient interruption of their entero-
hepatic circulation with no serious adverse events [14].
GSK2330672
GSK2330672 is a selective inhibitor of human IBAT and
it is designed to be a non-absorbable agent restricted to
the gastrointestinal (GI) tract. GSK2330672 is expected
to block the uptake of BAs in the terminal ileum, in-
crease their excretion in the faeces and decrease the
amount of BAs returning to the liver via enterohepatic
circulation (Fig. 1). Therefore treatment of PBC patients
with oral GSK2330672 is postulated to reduce concen-
trations of BAs in the systemic circulation and in turn
improve pruritus.
In phase I studies involving 42 healthy volunteers sin-
gle and repeat doses of GSK2330672 for 12 days were
shown to be safe and tolerable (ClinicalTrials.gov Identi-
fier: NCT01416324). GI symptoms were the most com-
mon reported drug-related adverse events (AEs). These
included diarrhoea, abdominal pain, bowel movement ir-
regularity and positive faecal occult blood tests. All AEs
were considered mild or moderate in severity.
Methods
Study design and overview
The BAT117213 study is a Phase 2a trial, designed to inves-
tigate treatment with GSK2330672 in PBC patients with
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pruritus (ClinicalTrials.gov Identifier: NCT01899703).
This is a multicentre, randomized, double-blind,
placebo-controlled, two-period cross-over trial which in
addition to studying the safety and efficacy of the drug
will provide an opportunity to conduct explorative studies
(including metabonomic and microbiomic studies) to de-
velop novel mechanistic insights into cholestatic pruritus.
Following written informed consent, patients with
PBC and pruritus were screened to establish study eligi-
bility. Eligible subjects participated in a two-week pla-
cebo run-in period followed by randomization in a
crossover fashion to receive placebo or GSK2330672
treatment during two consecutive two-week study pe-
riods (Sequence 1/Sequence 2) (Fig. 2). Subjects then
participated in a two-week follow up period of placebo
dosing. Total duration of the study was 56 days from the
first day of dosing.
Study population
The study population consisted of PBC patients with on-
going pruritus. All participants had a diagnosis of defin-
ite or probable PBC established according to recognised
criteria [2, 6]. Key inclusion and exclusion criteria for
study eligibility are detailed in Table 1. The trial entry
criteria for ongoing pruritus was defined as: i) severe
pruritus significantly impacting daily life and proven re-
fractory to medical therapy, or ii) pruritus that is newly
diagnosed or untreated, or iii) pruritus that is unresolved
with the use of a single antipruritic agent. To determine
subject eligibility for study enrolment outpatient screen-
ing was performed within 45 days before the first dose
administration. Subjects meeting all the inclusion criteria
Fig. 2 Flowchart of BAT117213 study design
Fig. 1 Mechanism of IBAT (ASBT) inhibitor drug. GSK2330672 interrupts the enterohepatic circulation of bile acids by selectively inhibiting the
IBAT protein located in the terminal ileum, thereby reducing the levels of bile acids in the systemic circulation. (Image reproduced with
permission from [31]). IBAT, ileal bile acid transporter; ASBT, apical sodium-dependent bile acid transporter
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and no exclusion criteria were enrolled by a designated
investigator from the centre.
Study objectives and outcomes
The primary objective of this trial is to investigate the
safety and tolerability of oral GSK2330672 compared
with placebo when administered for 14 days to PBC pa-
tients treated with UDCA. The secondary objectives are:
1) to evaluate the effects of oral GSK2330672 on sub-
jects’ experience of pruritus and its impact; 2) to demon-
strate the lack of effect of oral GSK2330672 on steady-
state pharmacokinetics (PK) of UDCA when UDCA is
administered alone or in combination with
GSK2330672; 3) to investigate the steady state PK of oral
GSK2330672; 4) to evaluate the effects of oral
GSK2330672 on total serum BA concentrations and
serum markers of BA synthesis [7-alpha-hydroxy-4-cho-
lesten-3-one (C4)]. Exploratory objectives of the study
include investigating effects of 14-day oral administra-
tion of GSK2330672 on markers of disease progression,
subject’s experience of benefits and disadvantages with
GSK2330672, metabonomics, microbiomics and
pharmacogenomics. The primary, secondary and ex-
ploratory outcome measures are given in Table 2.
Recruitment and consent
The study is a UK multicentre study and recruitment
was planned in three large, tertiary referral National
Health Service (NHS) hospitals based in Newcastle, Bir-
mingham and Cambridge. Patients were recruited from
the out-patient department cohorts of these hospitals
and in addition, trial information was published in news-
letters and magazines from the UK-PBC research group
and patient support groups (LIVErNORTH and PBC
Foundation). Any PBC patient interested in participating
Table 1 Eligibility criteria
A subject will be eligible for inclusion in this study only if all of the
following criteria apply:
1. Male or female aged between 18 and 75 years of age inclusive, at
the time of signing the informed consent.
2. Proven or likely PBC, as demonstrated by the patient presenting
with at least 2 of the following:
• History of sustained increased AP levels first recognized at least
6 months prior to Day 1
• Positive AMA titer (>1:40 titer on immunofluorescence or M2
positive by ELISA) or PBC-specific antinuclear antibodies (antinuclear
dot and nuclear rim positive)
• Liver biopsy consistent with PBC.
3. Screening AP value < 10 × ULN.
4. Subjects should be on stable doses of UDCA for >8 weeks at time
of screening. Subjects not taking UDCA due to intolerance may be
enrolled into this study following agreement by the GSK medical
monitor.
5. Symptoms of pruritus as follows (one of the following):
• PBC patients with severe symptoms of pruritus that significantly
impact daily life and have proven refractory after at least one
previous therapy has been discontinued due to inadequate clinical
response, poor tolerability or adverse events. Temporary response to
cooling, 1 % menthol in aqueous cream, nasobiliary drainage or
MARS therapy is still compatible with refractory itch.
• PBC patients with unresolved symptoms with use of a single
antipruritic agent who can tolerate washout of current therapy for
the duration of the trial.
• PBC patients seeking treatment for pruritus that is newly diagnosed
or previously untreated.
6. A female subject is eligible to participate if she is not pregnant, as
confirmed by a negative serum human chorionic gonadotropin (hCG)
test or at least one of the following conditions applies:
• Non-reproductive potential defined as pre-menopausal females with
a documented tubal ligation or hysterectomy; or postmenopausal de-
fined as 12 months of spontaneous amenorrhea
• Females on hormone replacement therapy (HRT) and whose
menopausal status is in doubt will be required to use one of the
highly effective contraception methods along with either a second
form of highly effective contraception or barrier protection (condoms
with spermicide) if they wish to continue their HRT during the study.
Otherwise, they must discontinue HRT to allow confirmation of post-
menopausal status prior to study enrolment.
• Reproductive potential and agrees to follow one of the specified
contraception options for the specified duration of time.
7. Capable of giving written informed consent, which includes
compliance with the requirements and restrictions listed in the
consent form.
Main exclusion criteria:
1. Screening total bilirubin >1.5x ULN. Isolated bilirubin >1.5xULN is
acceptable if bilirubin is fractionated and direct bilirubin <35 %.
2. Screening ALT or AST >4x ULN.
3. Screening serum creatinine >2.5 mg/dL (221 umol/L).
4. History or presence of hepatic decompensation (e.g., variceal
bleeds, encephalopathy, or poorly controlled ascites).
5. History or presence of other concomitant liver diseases including
hepatitis due to hepatitis B or C virus (HCV, HBV) infection, primary
sclerosing cholangitis (PSC), alcoholic liver disease, definite
autoimmune hepatitis or biopsy proven non-alcoholic steatohepatitis
(NASH).
6. Administration of the following drugs at any time during the
3 months prior to screening for the study: colchicine, methotrexate,
azathioprine, or systemic corticosteroids.
7. Current or chronic history of inflammatory bowel disease, chronic
diarrhoea, Crohn’s disease or diarrhoea related to malabsorption
syndromes.
8. Faecal occult blood positive test at screening.
9. Based on averaged QTc values of triplicate ECGs obtained at least
5 min apart:
• QTc≥ 450 msec; or
• QTc≥ 480 msec in subjects with Bundle Branch Block.
10. History of sensitivity to heparin or heparin-induced
thrombocytopenia.
11. History of sensitivity to any of the study medications, or
components thereof or a history of drug or other allergy that, in the
opinion of the investigator or GSK Medical Monitor, contraindicates
their participation.
12. History of regular alcohol consumption within 6 months of the
study defined as an average weekly intake of >21 units for males or
>14 units for females.
13. A positive pre-study drug/alcohol screen. A minimum list of drugs
that will be screened for include amphetamines, barbiturates, cocaine,
opiates, cannabinoids and benzodiazepines.
14. Where participation in the study would result in donation of
blood or blood products in excess of 500 mL within a 56 day period.
15. The subject has participated in a clinical trial and has received an
investigational product within the following time period prior to the
first dosing day in the current study: 30 days, 5 half-lives or twice the
duration of the biological effect of the investigational product (which-
ever is longer).
16. Exposure to more than four new chemical entities within
12 months prior to the first dosing day.
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in the study could contact the study team at the centre
nearest to their location either directly or via referral
from local primary or secondary care physicians. The
UK-PBC platform was utilised for recruitment using a
similar approach to the to the RIT-PBC trial reported re-
cently by our group [15]. The established UK-PBC data-
base was screened for patients with PBC-40 itch domain
scores meeting the definitions of persistent and/or se-
vere pruritus. The clinicians looking after these patients
were contacted to approach the patients and interested
patients were referred to their local recruiting centre. All
participants gave their written consent to participation
before screening investigations were performed. Par-
ticipants completed the consent process with study
investigators trained in Good Clinical Practice (GCP)
and assessment of capacity.
Randomisation
All eligible subjects enrolled in the study were rando-
mised to either Sequence 1 or Sequence 2 to receive oral
placebo or GSK2330672 for a 14-day period in a cross-
over fashion (Fig. 2). Sequence 1 was GSK2330672 for
14 days followed by placebo for 14 days and Sequence 2
was placebo for 14 days followed by GSK2330672 for
14 days. Randomisation was carried out via a dedicated
electronic system for randomisation-RAMOS (Random-
isation and Medication Ordering System) by generating
a unique randomisation number for each participant
that linked to the corresponding allocated sequence of
study drug.
Study treatment
The investigational medicinal product used in this
study was GSK2330672. The control intervention was
placebo. Both GSK233072 and placebo were manufac-
tured at a dedicated manufacturing unit in London
(UK) and dispensed as 30 g aliquots of oral solution
into amber glass bottles for distribution to participating
study centres. The study centres supplied solutions to
subjects in accordance with the randomization sched-
ule. Subjects consumed the entire quantity of one or
two bottles of study drug twice daily followed by two
50 mL rinses of water. All patients started the study
with 14-days placebo run in period followed by 14-days
treatment with GSK2330672 or placebo in a cross over
fashion.
Dose escalation and stopping criteria
The initial dose of GSK2330672 was 45 mg and all pa-
tients were asked to increase the dose to 90 mg on day
4. If this was not tolerated, they were asked to continue
at 45 mg and attempt a dose increase again two days
later. If 90 mg could not be tolerated by the end of day
7, subjects were asked to continue only 45 mg.
Following stopping criteria were in place to assure
subject safety: 1) to stop the study treatment if the stop-
ping criteria for liver chemistry were met [ALT >5-8 x
upper limit of normal (ULN), bilirubin > 1.5-2 x ULN],
and 2) to withdraw the subject from the study if cor-
rected QT (QTc) interval withdrawal criteria were met
based on their average values on triplicate ECGs sepa-
rated by five minutes. These were QTc > 500 msec, or
uncorrected QT >600 msec, or QTc >60 msec change
from baseline). If a subject met the stopping criteria, ap-
propriate safety follow-up assessments and procedures
were completed.
Table 2 Primary, secondary and exploratory outcome measures
of the BAT117213 study
1. Primary outcome measures:
• Safety assessment following repeat doses of oral GSK2330672
Safety will be assessed using clinical haematology, clinical chemistry,
urinalysis, single 12-lead electrocardiograms (ECGs), vital sign mea-
surements including systolic and diastolic blood pressure (BP) and
pulse rate.
• Tolerability assessment using Gastrointestinal Symptom Rating Scale
(GSRS)
Subjects will be asked to complete GSRS, a validated scale and the
scale will be used to assess symptoms experienced by subject over
the preceding 5 to 7 days
• Faecal occult blood (FOB) testing
FOB monitoring for symptomatic or visible gastrointestinal bleeding
or asymptomatic occult bleeding
2. Secondary outcome measures:
• Subject reported outcomes-daily pruritus 0 to 10 point scale
This scale will be implemented to measure symptoms of itching as
well as other associated symptoms twice daily in the morning and
evening (approximately the time of drug dosing). The severity of
itching symptoms from “0” (no itching) to “10” (worst possible
itching) will be recorded
• Subject reported outcomes-5D-itch scale
The 5-D itch scale covers five dimensions of itching experienced by
subjects including duration, degree, direction, disability and
distribution
• Subject reported outcomes-PBC-40 quality of life (QoL) scale
The PBC-40 QoL scale has six domains; cognitive, itch, fatigue, social,
emotional and (other) symptoms
• Measurement of serum profiles of total bile acid concentrations and
7-alpha hydroxy-4-cholesten-3-one (C4). C4 is the first committed step
of bile acid synthesis from cholesterol
• Steady-state pharmacokinetics (PK) assessment of UDCA and its tau-
rine and glycine conjugates taurodeoxycholic acid (TUDCA) and gly-
coursodeoxcholic acid (GUDCA).
Blood sample will be collected for measurements of steady state PK
parameters of UDCA and its metabolites including maximum
observed plasma concentration (Cmax), time to Cmax (tmax) and
terminal phase half-life (t1/2).
3. Exploratory outcome measures:
• Markers of disease progression: ALT/AST, AP, GGT, bilirubin, albumin,
PT/INR
• An exit interview conducted at end of follow-up phase to assess
subject’s experience of benefits and disadvantages with GSK2330672
• Pharmacogenomics for genes related to pruritus and GSK2330672
response
• Metabonomics to study serum bile acid species, serum autotaxin
and FGF-19 before and after treatment with GSK2330672
• Microbiomics to study gut microbiota in PBC patients with pruritus
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Concomitant medications
Before starting the study, all patients were advised to
stop using their usual anti-pruritic agents including cho-
lestyramine, colesevelam, rifampicin, naltrexone, sertra-
line, gabapentin and anti-histamines. The use of these
medications was prohibited during the study period until
the final follow-up period when rescue medications were
permitted. Application of topical agents used to relieve
pruritus was permitted during the study only if agents did
not contain active ingredients in the list of prohibited
agents and with prior agreement of the clinical investiga-
tor. Subjects were asked to abstain from taking new pre-
scription or new non-prescription drugs (including
vitamins and dietary or herbal supplements), from the
start of the placebo run-in period until completion of
the follow-up visit. The use of UDCA was permitted
and patients who were on UDCA were standardised to
receive Ursofalk®(Dr. Falk Pharma UK Ltd) once daily
preparation at dose 13–15 mg/kg/day and instructed to
take it at bed time.
Patient reported outcomes
Existing patient reported outcome (PRO) measures to
assess the impact of PBC symptoms include the PBC-40,
a widely acceptable, validated, disease-specific question-
naire and the 5-D Itch scale [16, 17]. However, for this
study a more specific PRO measure was needed that
could detect the severity and variability of pruritus and
other PBC symptoms and potential treatment effects on
a daily basis with a short recall period. The development
of such a measure began with interviews with PBC pa-
tients to identify additional characteristics of pruritus
and other symptoms and their impact on sleep and daily
activities. With input from PBC patients and PRO ex-
perts a new electronic patient reported outcome (ePRO)
diary was developed to assess the severity of the pruritus
and other PBC symptoms. Subjects completed the ePRO
diary every morning and evening before dosing the study
drug. In the ePRO diary pruritus severity was rated using
a numerical rating scale (NRS). Psychometric testing to
support the validity and reliability of the ePRO will be
evaluated with data from the current clinical study.
Data analysis
Statistical analysis
This trial is designed to estimate the effect of study drug
GSK2330672 relative to placebo when co-administered
with UDCA on pruritus symptom, markers of efficacy
and disease progression and the PK of UDCA. No for-
mal hypothesis will be tested.
The efficacy endpoint in this study is the patient re-
ported rating of pruritus severity scores. Pruritus will be
measured in three different PROs: pruritus NRS using the
ePRO, the 5-D itch scale and the PBC-40 questionnaire
[16, 17]. Changes in pruritus NRS will be used as the key
measure of the efficacy endpoint and will be analysed
using a mixed effects model with fixed effect terms for
treatment period and sequence to examine differences be-
tween GSK2330672 and placebo. Subject will be treated as
a random effect in the model. Point estimates and their
associated 95 % confidence interval (CI) will be con-
structed for the mean differences in pruritus severity
scores.
Data from subjects that are co-administered UDCA as
part of their standard care will be analysed similarly for
PK endpoints. Following log-transformation, maximum
observed plasma concentration (Cmax), AUC (0–12 h)
and AUC (12–24 h) of UDCA and glycine and taurine
conjugated metabolites of UDCA (TUDCA and
GUDCA) will be separately analysed. This will be done
using a mixed effects model with fixed effect terms for
treatment period and sequence to examine differences
between UDCA administration with and without
GSK2330672. Point estimates and corresponding 90 %
CI will also be constructed for the difference and/or ra-
tio between the mean of the test treatment (UDCA plus
GSK2330672) and the mean of the reference treatment
(UDCA alone).
Sample size
The efficacy endpoint in this study is pruritus score and
the sample size for efficacy endpoint is based on the
pruritus 0 to 10 points scale. On this scale the average
effect of rifampicin is 1.62 points and the reported
pooled total standard deviations of various anti-pruritic
drugs ranges from 1.22 to 3.84 points [18, 19]. Assuming
that GSK2330672 is at least as effective as rifampicin, a
sample size of 40 will result in a reasonable power (>90
%) if the standard deviation (SD) is 3.1 points or less.
For estimation of relative bioavailability 20 subjects tak-
ing UDCA are required to ensure that the resultant 90
% CI of the ratio will be within 0.8 and 1.25 assuming
that the true ratio is 1 and the SD on the log10 scale is
less than 0.25.
An initial sample-size of 40 subjects was selected
based on considerations of both efficacy and PK end-
points. However, due to the uncertainty around
sample-size assumptions a series of interim analyses
for futility and possible sample-size re-estimation
were carried out at regular intervals. Data from com-
pleted patients were reviewed by an unblinded review
committee (composed of GSK personnel not directly
involved in study conduct). As the probability of
demonstrating sufficient difference was high, the
sponsor revised the sample-size from 40 to 22. No
other changes to study conduct were planned as a re-
sult of the interim analyses.
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Conduct of the trial
The conduct of the trial followed the principles outlined
in the NHS research governance framework for health
and social care, GCP and the guiding principles of the
2008 Declaration of Helsinki. The trial involved the par-
ticipant visiting the study centre a total of six times in-
cluding screening visit, day 1 visit, three consecutive
fortnightly in-patient stays (each up to 36 h) and a fol-
low up visit. The schedule of study procedures during
these visits and data collection is summarised in Table 3.
Protocol deviation or exemptions were not allowed
with the exception of immediate safety concerns. All In-
vestigators at recruiting sites followed standard operative
procedures for collection, handling, processing and stor-
age of samples (blood, urine and stool) collected at study
visits. All clinical and non-clinical subject data including
medical history (to capture co-morbidities and concomi-
tant medications) and physical examinations were en-
tered into electronic case report forms (eCRFs). No
patient identifiable information was entered in the
eCRFs. All participants were allocated a unique study
identifier which was used on eCRFs transmitted elec-
tronically to the sponsor and combined with data pro-
vided from other sources in a validated data system.
Study monitoring
The study sponsor performed periodic monitoring at
each study centre to monitor the study conduct and site
activity. The monitor had direct access to all relevant
documents to verify the data for completeness, accuracy
and authenticity and the site’s compliance with study
protocol. All monitoring findings were reported and
followed up in a timely manner. Periodic interim ana-
lysis of the trial were undertaken to determine as to
whether the study should be modified, continued or
terminated.
Adverse events
AEs and serious adverse events (SAEs) were collected
from the start of the placebo run-in period (day 1) until
the follow-up contact (day 56). The investigator and site
staff were responsible for detecting, documenting and
reporting events that meet the definition of an AE or
SAE. All SAEs were recorded and reported to the study
sponsor within 24 h. Periodic reviews of the safety data
were performed and presented during interim analysis to
both the sponsor and the study investigators.
Sponsorship, insurance and indemnity
In accordance with the Association of the British
Pharmaceutical Industry (ABPI) guidance, the trial spon-
sor had policies in place regarding compensation for any
trial related harm due to negligence or otherwise. The
trial sponsor had insurance to cover indemnity in
respect of potential liability arising from negligent harm
related to study design. Due to the commercial nature of
the study there were also arrangements for non-
negligent compensation. The participating study centres
were NHS hospitals and the NHS indemnity covered
NHS staff and medical academic staff with honorary
NHS contracts conducting the study for potential liabil-
ity in respect of negligent harm arising from the conduct
of the study.
Trial status
The BAT117213 study was opened for recruitment in
January 2014 with first patient recruited in March 2014.
The initial recruitment target was 40 subjects. Following
review of safety and efficacy of data from 11 patients at
the first interim analysis in March 2015, the sponsor
decided to continue the study recruitment. A second in-
terim analysis of the data from 19 patients was per-
formed in July 2015 and the sponsor decided to reduce
the total sample size to 22 patients. The recruitment
ended in October 2015 with all 22 patients randomised
from two trial sites (Newcastle 13; Birmingham 9). The
treatment follow-up of participants was completed in
December 2015. The analysis of study data is currently
ongoing and results are scheduled to be available in No-
vember 2016.
Discussion
Need for novel anti-pruritic drugs in PBC
Pruritus is a complex symptom and the drug treatment
of pruritus in PBC patients remains a challenge in clin-
ical practice. The four main classes of drugs that are rec-
ommended by current guidelines [2, 6] include bile acid
sequestrants (cholestyramine), enzyme inducers (rifam-
picin), opioid antagonists (naltrexone) and selective sero-
tonin re-uptake inhibitors (sertraline). These drugs are
limited by their lack of universal efficacy, poor compli-
ance (especially cholestyramine) and the need for regular
monitoring for liver toxicity (rifampicin). Cholestyr-
amine and rifampicin have good reports but clinical ex-
perience of both naltrexone and sertraline has been
disappointing for many clinicians [2].
A critical review of literature shows that the strength
of evidence for current anti-pruritic drug therapy is
poor. Cholestyramine, the current first-line therapy was
last studied over five decades ago but has never been
subjected to randomised placebo-controlled trials and
has evidence category II-2 (cohort or case control ana-
lytical studies) [20–24]. Only rifampicin and naltrexone
have been studied in controlled trials [18, 19, 25–27]
and sertraline (evidence category II-2) is the last agent
investigated with a positive outcome on pruritus [28]. A
number of other drugs have been investigated but with
little success and more recently both gabapentin (2006)
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Table 3 BAT117213 study: schedule of procedures and data collection
Period
description
Screening Placebo run-in Treatment period 1 Treatment period 2 Follow-upf
Day (relative to
Day 1)
-45 to-
1 days
1 2–
12
13 14 15 16–
26
27 28 29 30–
40
41 42 43 44 45–
55
56
Admission to
Unit
X X X
Discharge X X X
Outpatient visit X X X
Screening
assessmentsa
X
Brief Physical X X
12-lead ECGb X X X X X X
Vital signs X X X X X X
Urine drug/
alcohol screen
X X X X X X
β-hcg (women) X X X X X X
standard blood
tests and
urinalysis
X X X X X
Randomisation X
Study
treatment
dosing
X X X X X X X X X X X X X X X
Concomitant
medication
review
X X X X X
Meal served X X X X X X X X X
Blood samplesc X X X
Metabonomics
(Stool and
urine)
<——————————————————> <——————————————————> <———————————————>
Microbiomics
(Stool)
<——————————————————> <——————————————————> <———————————————>
PBC-40
questionnaired
X X X X X
GSRSd X X X X X
5-D Itch scaled X X X X X
Faecal Occult
blood
X X X X X
H
egade
et
al.BM
C
G
astroenterology
 (2016) 16:71 
Page
8
of
12
Table 3 BAT117213 study: schedule of procedures and data collection (Continued)
Pruritus 0–10
point scale
(electronic
diary)e
<———————————————————————————————————————————————————————————————————>
AE assessment <———————————————————————————————————————————————————————————————————>
PGx For subjects who consent only. Collect one PGx sample after the start of dosing, preferably on day 1
Exit interview X
aScreening assessments: informed consent for the study and PGX; demographics; complete physical; medical/medication/drug/alcohol history; Hepatitis B and Hepatitis C screen
bSingle ECG to be performed, with the exception of screening and day 14 when this will be in triplicate
cBlood samples for GSK2330672, UDCA, bile acids, bile acid species, C4, Autotaxin, FGF19 and metabonomics
dpatient reported outcome (PRO) assessments. On days in which PRO assessments are administered at study visits they should be administered before any other study procedure
esymptoms recorded twice daily (pre-dose of study drug)
fRescue treatment with antipruritic agents can be instituted in subjects with severe itching during the placebo follow up period
H
egade
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and colesevelam (2010) trials failed to show any thera-
peutic benefit in cholestatic pruritus [29, 30].
IBAT2330672 trial
The apparent lack of novel drug development in chole-
static pruritus can be attributed partly to incomplete un-
derstanding of the complex pathophysiology of the
disease. More recent advances in molecular research
have identified novel targets for drug development in
cholestasis. IBAT inhibitors are novel class of drugs with
therapeutic potential in cholestasis. They have been
shown be beneficial in cholestasis by the experimental
studies and their desired effects on serum and faecal bile
acid profile has been proven in healthy people [13, 14].
The BAT117213 study is the first phase 2 multicentre,
double-blinded, placebo-controlled crossover trial de-
signed to investigate the safety and efficacy of IBAT in-
hibitor in PBC patients with pruritus. Unlike the only
other phase 2 trial of an IBAT inhibitor drug (LUM001)
in PBC (CLARITY study, NCT01904058), the main
strength of the BAT117213 study is its crossover design
which allows estimating the treatment effect in a smaller
number of patients and reduces the between-patient
variability and yields a more efficient comparison of
treatments than a similar sized parallel group trial. In
the BAT117213 study every patient will receive both the
study drug and the placebo; therefore each patient will
serve as his/her own matched control.
An additional strength of this trial is the utility of pa-
tient reported outcomes to measure the treatment re-
sponse objectively using existing validated tools
including the PBC-40 questionnaire and 5-D itch scale
as well as a novel, easy-to-use electronic symptom diary.
The latter has been specifically developed for this study
and it contains morning and evening diaries with ques-
tions on itch, fatigue and concentration to comprehen-
sively capture the severity of the symptoms over the
preceding 12 h. In addition, the exit interviews con-
ducted at the end of the study provide the opportunity
for patients to express their experiences in the study in a
semi-structured method that may not have been de-
tected with the more structured patient reported out-
comes measures.
The BAT117213 study also provides a unique oppor-
tunity to conduct novel, explorative, mechanistic re-
search in patients with cholestatic pruritus. Serum and
urine samples obtained during the study will be used to
study the metabolic phenotype (metabonomics) of prur-
itus in PBC by using 1H (proton)-nuclear magnetic res-
onance (NMR) spectroscopy and mass spectrometry
(MS). Similarly, using the faecal samples from study pa-
tients gut-microbiome studies will be undertaken to
study the association between gut microbiota compos-
ition and pruritus in PBC. Results of these metabonomic
and microbiomic studies are likely to provide more
insight into the biology of pruritus in PBC and may
identify potential biomarkers for cholestatic pruritus.
The main drawback of this trial is the potential carry-
over effect (i.e. effect of the treatment from the previous
time period may “carry over” on the response to subse-
quent period) and lack of “washout period” between
treatment periods. Carryover effect is a common prob-
lem inherent to the cross over study design and may po-
tentially confound direct estimates of treatment effect.
Therefore the statistical analysis the data will be assessed
for any evidence of carry over and appropriate sensitivity
analyses will be performed. To mitigate against the lack
of “washout period” the outcome measurements will be
restricted to the latter part of each treatment period.
In summary, BAT117213 study is a phase 2 study to
evaluate the safety and tolerability of a unique class of
drug in treating pruritus in PBC patients and provide
novel information about bile acids and metabolic
changes and gut microbiome profile in cholestatic prur-
itus. The results from this trial will inform the trial de-
sign of future development phase of the IBAT inhibitor
drug.
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